Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial

Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial is a phase 2, interventional study registered as NCT07106034 by Shanghai Pudong Hospital, with a registry enrolment figure of 32 participants, started 2025-08-31 and due to reach its primary completion in 2027-07-31. Interventions recorded: Ongericimab + Toripalimab + Bevacizumab + FOLFOX; Ongericimab + Toripalimab + Bevacizumab + FOLFIRI. Conditions listed: Advanced Colorectal Cancer. Primary outcome: overall response rate. Colorectal eligibility wording from the registry: "Histologically confirmed MSS/pMMR colorectal or rectal cancer, who have progressed on first-line fluoropyrimidine - based combination therapy (including progression during maintenance therapy)". Sites: China. No results are recorded here; the registry entry is the source.